Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

Abstract Title:

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Abstract Source:

Diabetes Obes Metab. 2012 Dec 26. Epub 2012 Dec 26. PMID: 23279307

Abstract Author(s):

Kaj Stenlöf, William T Cefalu, Kyoung-Ah Kim, Maria Alba, Keith Usiskin, Cindy Tong, William Canovatchel, Gary Meininger

Article Affiliation:

Clinical Trial Center, Sahlgrenska University Hospital, Gothenburg, Sweden.

Abstract:

AIMS: Canagliflozin is a sodium glucose co-transporter 2 inhibitor in development for type 2 diabetes mellitus (T2DM). The efficacy and safety of canagliflozin were evaluated in subjects with T2DM inadequately controlled with diet and exercise. METHODS: In this 26-week, randomized, double-blind, placebo-controlled, phase 3 trial, subjects (N = 584) received canagliflozin 100 or 300 mg or placebo once daily. Primary endpoint was the change from baseline in HbA(1c) at Week 26. Secondary endpoints included the proportion of subjects achieving HbA(1c)<7.0%; change from baseline in fasting plasma glucose (FPG), 2-hour postprandial glucose (PPG), and systolic blood pressure (BP); and percent change in body weight, high-density lipoprotein cholesterol (HDL-C), and triglycerides. Adverse events (AEs) were recorded throughout the study. RESULTS: At Week 26, HbA(1c) was significantly reduced from baseline with canagliflozin 100 and 300 mg compared with placebo (-0.77%, -1.03%, and 0.14%, respectively; p<0.001 for both). Both canagliflozin doses significantly decreased FPG, 2-hour PPG, body weight, and systolic BP (p<0.001 for all), and increased HDL-C compared with placebo (p<0.01 for both). Overall incidences of AEs were modestly higher with canagliflozin versus placebo; rates of serious AEs and AE-related discontinuations were low and similar across groups. Incidences of genital mycotic infections, urinary tract infections, and osmotic diuresis-related AEs were higher with canagliflozin; these led to few discontinuations. The incidence of hypoglycaemia was low across groups. CONCLUSION: Canagliflozin treatment improved glycaemic control, reduced body weight, and was generally well tolerated in subjects with T2DM inadequately controlled with diet and exercise.

Study Type : Human Study

Print Options


Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2019 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.